Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Corvus Pharmaceuticals, Inc. CRVS

Healthcare  —  Biotechnology
11.62 (0.18) (1.53%) as of 25 Sep
Market cap
$992.6M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Corvus Pharmaceuticals, Inc. (CRVS) Business Profile

Updated before January 2025

Company Overview

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative immuno-oncology therapies. Founded in 2014 and headquartered in Burlingame, California, Corvus was established by a team of seasoned biotechnology executives, including Richard A. Miller, M.D., who serves as the company’s President and Chief Executive Officer. Dr. Miller is a recognized leader in the field of oncology drug development, having co-founded and led several successful biotech companies prior to Corvus. The company’s mission is to harness the power of the immune system to treat cancer and other serious diseases, with a focus on developing therapies that target the adenosine pathway and other immune checkpoints.

Corvus operates with a lean and focused team of scientists, clinicians, and business professionals, all working toward advancing its pipeline of novel therapies. The company’s leadership team brings decades of experience in drug discovery, clinical development, and commercialization, positioning Corvus as a key player in the rapidly evolving immuno-oncology landscape.

Core Business Segments

Corvus Pharmaceuticals is primarily focused on the development of immuno-oncology therapies. Its core business segments include:

Adenosine Pathway Inhibitors

Corvus is a pioneer in targeting the adenosine pathway, a critical mechanism by which tumors evade immune system detection. The company’s lead product candidate, ciforadenant, is a small molecule antagonist of the adenosine A2A receptor. Ciforadenant is being evaluated in clinical trials for the treatment of various cancers, including renal cell carcinoma and non-small cell lung cancer. By blocking the A2A receptor, ciforadenant aims to restore immune cell activity and enhance the body’s natural ability to fight cancer.

ITK Inhibitors

Another key area of focus for Corvus is the development of ITK (interleukin-2-inducible T-cell kinase) inhibitors. The company’s ITK inhibitor, CPI-818, is designed to selectively target T-cell malignancies, such as peripheral T-cell lymphoma. CPI-818 is currently in early-stage clinical trials and represents a novel approach to treating these aggressive cancers.

Anti-CD73 Antibodies

Corvus is also developing monoclonal antibodies targeting CD73, an enzyme that plays a role in the production of adenosine. The company’s anti-CD73 antibody, mupadolimab, is being studied for its potential to enhance immune responses in cancer and infectious diseases, including COVID-19. Mupadolimab is designed to block CD73 activity and stimulate the immune system, offering a complementary approach to other immuno-oncology therapies.

Business Model

Corvus Pharmaceuticals operates as a research-driven organization with a focus on clinical development and strategic partnerships. The company generates revenue primarily through collaborations, licensing agreements, and milestone payments from its partners. By advancing its pipeline of innovative therapies through clinical trials, Corvus aims to achieve regulatory approvals and ultimately commercialize its products.

The company’s business model emphasizes:

  • Innovation: Corvus invests heavily in research and development to discover and advance novel therapies.
  • Collaboration: The company seeks partnerships with academic institutions, pharmaceutical companies, and other stakeholders to accelerate the development and commercialization of its products.
  • Focus: Corvus maintains a streamlined portfolio, concentrating its resources on high-potential drug candidates.

Strategic Direction

Corvus Pharmaceuticals is committed to advancing its pipeline of immuno-oncology therapies and expanding its presence in the biopharmaceutical industry. Key strategic priorities include:

  • Pipeline Expansion: The company plans to explore additional indications for its existing drug candidates and identify new targets within the adenosine pathway and other immune checkpoints.
  • Global Reach: Corvus aims to establish partnerships and collaborations to bring its therapies to patients worldwide.
  • Sustainability: The company is focused on maintaining financial discipline and operational efficiency to ensure long-term sustainability.
  • Innovation: Corvus continues to invest in cutting-edge research to stay at the forefront of immuno-oncology.

Competitive Landscape

Corvus Pharmaceuticals operates in a highly competitive environment, with numerous companies developing immuno-oncology therapies. Key competitors include:

  • AstraZeneca: A leader in immuno-oncology, AstraZeneca develops checkpoint inhibitors and other cancer therapies.
  • Bristol-Myers Squibb: Known for its blockbuster immunotherapy drugs, such as Opdivo and Yervoy.
  • Merck & Co.: The developer of Keytruda, one of the most successful immuno-oncology drugs on the market.
  • Incyte Corporation: Focused on small molecule inhibitors and other targeted therapies.
  • Arcus Biosciences: A direct competitor in the adenosine pathway space, developing therapies targeting A2A receptors and CD73.

Risk Factors

Corvus Pharmaceuticals faces several risks that could impact its business operations and financial performance:

  • Clinical Trial Risks: The success of the company’s drug candidates depends on the outcomes of clinical trials, which are inherently uncertain.
  • Regulatory Risks: Delays or failures in obtaining regulatory approvals could hinder the commercialization of Corvus’s therapies.
  • Market Competition: The immuno-oncology market is highly competitive, with numerous established players and emerging startups.
  • Financial Risks: As a clinical-stage company, Corvus relies on external funding and may face challenges in securing additional capital.
  • Supply Chain Disruptions: The company’s operations could be affected by disruptions in the supply of raw materials or manufacturing processes.

Recent Developments

Corvus Pharmaceuticals has made significant progress in advancing its pipeline and corporate strategy. Recent highlights include:

  • Clinical Trial Updates: The company announced positive interim results from its ongoing clinical trials of ciforadenant and CPI-818, demonstrating promising efficacy and safety profiles.
  • COVID-19 Research: Corvus expanded its research efforts to include the development of mupadolimab for the treatment of COVID-19, leveraging its expertise in immunology.
  • Partnerships: The company entered into strategic collaborations with leading academic institutions to accelerate the development of its therapies.
  • Corporate Milestones: Corvus successfully raised additional capital through public offerings, strengthening its financial position.

Investment Considerations

Investors considering Corvus Pharmaceuticals should weigh the following factors:

Strengths

  • Innovative Pipeline: Corvus is developing first-in-class and best-in-class therapies targeting the adenosine pathway and other immune checkpoints.
  • Experienced Leadership: The company’s management team has a proven track record in oncology drug development.
  • Strategic Focus: Corvus maintains a clear focus on high-potential drug candidates and partnerships.

Risks

  • Early-Stage Development: As a clinical-stage company, Corvus has no approved products and relies on external funding.
  • Market Competition: The immuno-oncology space is crowded, with numerous competitors vying for market share.
  • Regulatory Uncertainty: The approval process for new therapies is complex and time-consuming.

Conclusion

Corvus Pharmaceuticals, Inc. is a promising player in the field of immuno-oncology, with a strong focus on innovative therapies targeting the adenosine pathway and other immune checkpoints. While the company faces significant risks as a clinical-stage organization, its experienced leadership, strategic focus, and robust pipeline position it for long-term success. As Corvus continues to advance its therapies through clinical trials and explore new opportunities, it remains well-positioned to make a meaningful impact on the treatment of cancer and other serious diseases.